July 31st 2025
EyePoint Pharmaceuticals completes enrollment for the LUCIA trial, advancing DURAVYU's potential as a new treatment for wet AMD.
The company presented topline Phase I/II first-in-human results at the 127th American Academy of Ophthalmology annual meeting in San Francisco, demonstrating significant improvement in visual field, in concordance with trended improvements in visual acuity and functional vision.
Read More
AAO 2023: OTT166 progress: OcuTerra's diabetic retinopathy treatment
November 3rd 2023Kerrie Brady, president and chief executive officer of OcuTerra Therapeutics, shares progress in their Phase 2 DR:EAM Diabetic Retinopathy study, with promising results expected in Q1 2024 for their innovative eye drop treatment, OTT166.
Read More
FDA grants Toku Breakthrough Device status for its cardiovascular risk AI platform
November 2nd 2023The company’s AI CLAIR technology platform has received FDA breakthrough device status, and if cleared by the FDA will deliver real-time cardiovascular disease risk assessments through routine eye exams.
Read More
Clearside Biomedical completes recruitment in ODYSSEY Phase 2b clinical trial of CLS-AX in wet AMD
November 1st 2023The clinical trial will evaluate the safety and efficacy of CLS-AX (axitinib injectable suspension), a tyrosine kinase inhibitor. According to the company, topline data is expected during the third quarter of 2024.
Read More
FDA approves faricimab-svoa for the treatment of retinal vein occlusion
October 27th 2023According to Genentech, RVO is the third indication for Vabysmo, in addition to wet, or neovascular, age-related macular degeneration and diabetic macular edema. The approval is based on two Phase III studies demonstrating early and sustained vision improvements that were non-inferior to aflibercept.
Read More
Study: “Pseudo cell” formulation targets vitreoretinal disease
October 26th 2023Researchers have delved into the possibility of cell-based therapy in ophthalmology. By targeting vitreoretinal diseases, they are tackling a range of vision-threatening disorders which often result in severe irreversible vision loss.
Read More
NeuroOp Guru: Two cases of CRAO occurring immediately postoperatively
October 22nd 2023Andrew Lee, MD, and Andrew Carey, MD, sit down on another episode of the NeuroOp Guru to discuss 2 cases of CRAO immediate post-op uncomplicated cataract surgery under topical anesthesia treated with intra-ophthalmic artery fibrinolysis within 6 hours after symptom onset.
Watch
Arctic Vision completes enrollment in Phase 3 trial for uveitic macular edema treatment ARCATUS
October 7th 2023This milestone was announced by Clearside Biomedical, Inc., Arctic Vision's partner. ARCATUS, also known as XIPERE®, utilizes a revolutionary suprachoroidal delivery platform, offering new hope to patients in China suffering from this vision-threatening condition.
Read More
ZEISS Medical Technology and Boehringer Ingelheim announce long-term collaboration
October 6th 2023The collaboration will drive an effort to develop predictive analytics to enable early detection of eye diseases and more personalized treatments to prevent vision loss for people with serious eye diseases.
Read More
World Retina Day: New data from Kiora Pharmaceuticals shines a light on inherited retinal diseases
September 24th 2023Kiora CEO Brian Strem, PhD, offers an update on the development of KIO-301, a molecule that selectively targets retinal ganglion cells, giving them the ability to sense light.
Read More
The research will focus on the compound's impact on biomolecular condensates, which are implicated as a key driver of pathology in neurodegeneration and diseases impacting high metabolic organs. Because the retina is one of the highest energy consuming systems in the human body, deficits in energy supply can be catastrophic.
Read More
Study: Researchers find new mechanisms that cause blindness, opening the door to future treatments
September 22nd 2023Researchers from the University of Barcelona are looking to unlock the function of genes in order to design therapies to treat patients diagnosed with retinitis pigmentosa.
Read More
Ocugen announces positive clinical study update from the phase 1/2 trial of OCU400
September 13th 2023According to the company, the clinical study update suggests continued positive trends in best-corrected visual acuity and multi-luminance mobility testing as well as positive trends in low-luminance visual acuity among treated eyes.
Read More